Anti-CD19 antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-12478689-B2
Application number	US-202418920375-A
Country	US
Kind code	B2
Filing date	Oct 18, 2024
Priority date	Jun 16, 2022
Publication date	Nov 25, 2025
Grant date	Nov 25, 2025

Abstract

The present disclosure provides anti-CD19 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

First claim

What is claimed:

1 . An anti-CD19 antibody comprising:
a heavy chain variable region comprising a CDR-H1 domain, CDR-H2 domain, and a CDR-H3 domain; and a light chain variable region comprising a CDR-L1 domain, a CDR-L2 domain, and a CDR-L3 domain, wherein the CDR-H1 domain comprises the amino acid sequence GFTFTTYWIN (SEQ ID NO: 1, the CDR-H2 domain comprises the amino acid sequence NIYPSDSYTNYNQKFKD (SEQ ID NO: 2), the CDR-H3 domain comprises the amino acid sequence EDYYGSSSYYAMDY (SEQ ID NO: 3); the CDR-L1 domain comprises the amino acid sequence KASQDVGTAVA (SEQ ID NO: 4, the CDR-L2 domain comprises the amino acid sequence WASTRHT (SEQ ID NO: 5), and the CDR-L3 domain comprises the amino acid sequence QQYSTYPLT (SEQ ID NO: 6).

2 . The anti-CD19 antibody according to claim 1 , wherein the antibody is an IgG1 antibody.

3 . The anti-CD19 antibody according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 8.

4 . The anti-CD19 antibody according to claim 3 , wherein the antibody is an IgG1 antibody.

5 . The anti-CD19 antibody according to claim 1 , wherein the antibody comprises:
two heavy chains, wherein both heavy chains each consist of the amino acid sequence set forth as SEQ ID NO: 9; and two light chains, wherein both light chains each consist of the amino acid sequence set forth as SEQ ID NO: 10.

6 . The anti-CD19 antibody according to claim 5 , wherein the antibody is afucosylated.

7 . The anti-CD19 antibody according to claim 5 , wherein the antibody is afucosylated at position 303 of SEQ ID NO: 9.

8 . The anti-CD19 antibody of claim 1 , wherein the antibody comprises:
two heavy chains, wherein both heavy chains consist of the amino acid sequence set forth as SEQ ID NO: 11; and two light chains, wherein both light chains each consist of the amino acid sequence set forth as SEQ ID NO: 10.

9 . The anti-CD19 antibody according to claim 8 , wherein the antibody is afucosylated.

10 . The anti-CD19 antibody according to claim 8 , wherein the antibody is afucosylated at position 303 of SEQ ID NO: 11.

11 . The anti-CD19 antibody of claim 1 , wherein the antibody comprises:
two heavy chains, wherein one heavy chain consists of the amino acid sequence set forth as SEQ ID NO: 9, and one heavy chain consists of the amino acid sequence set forth as SEQ ID NO: 11; and two light chains, wherein both light chains each consist of the amino acid sequence set forth as SEQ ID NO: 10.

12 . The anti-CD19 antibody according to claim 11 , wherein the antibody is afucosylated.

13 . The anti-CD19 antibody according to claim 11 , wherein the antibody is afucosylated at position 303 of SEQ ID NO: 9 and at position 303 of SEQ ID NO: 11.

Assignees

• Abbvie Biotherapeutics Inc

Inventors

• Purcell James W

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6803 Primary

  Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title

• A61K47/6889

  Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment · CPC title

• C07K2317/41

  Glycosylation, sialylation, or fucosylation · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title